Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quart...(136795 Consolidated Balance Sheet Dat...),Health

Date:4/28/2009

136,795 Consolidated Balance Sheet Data As of As of March 31, December 31, (In thousands) 2009 2008 (unaudited) Cash and investments, including cash and investments held by Symphony Icon, Inc. $145,467 $158,798 Property and equipment, net 63,027 65,087 Goodwill 25,798 25,798 Total assets 244,452 261,508 Deferred revenue 17,321 19,884 Current and long-term debt 44,923 30,492 Noncontrolling interest in Symphony Icon, Inc. 7,470 10,247 Accumulated deficit (508,955) (487,395) Total Lexicon Pharmaceuticals, Inc. stockholders' equity 165,822 185,580

'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)